Akcea Therapeutics, Inc. (AKCA)


Stock Price Forecast

Oct. 9, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Akcea Therapeutics, Inc. chart...

About the Company

Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.

Sector

Health Technology

Industry

Pharmaceuticals: Major

Employees

294

CEO

Damien McDevitt

Exchange

NASDAQ

Website

http://www.akceatx.com

$337M

Total Revenue

294

Employees

$2B

Market Capitalization

-49.11

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AKCA News

An Intrinsic Calculation For Akcea Therapeutics, Inc. (NASDAQ:AKCA) Suggests It's 48% Undervalued

1y ago, source: AOL

Today we will run through one way of estimating the intrinsic value of Akcea Therapeutics, Inc. (NASDAQ:AKCA) by projecting its future cash flows and then discounting them to today's value.

Akcea Therapeutics, Inc. Just Recorded A 13% Earnings Beat: Here's What Analysts Think

4y ago, source: Yahoo Finance

As you might know, Akcea Therapeutics, Inc. (NASDAQ:AKCA) just kicked off its latest full-year results with some very strong numbers. Akcea Therapeutics beat revenue and statutory earnings per share ...

Ionis Pharmaceuticals

10d ago, source: Forbes

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.

PTCT PTC Therapeutics, Inc.

1mon ago, source: Seeking Alpha

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally.

Kintara Therapeutics Inc KTRA

19h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Ovid Therapeutics Inc OVID

15h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

EFTR eFFECTOR Therapeutics, Inc.

19h ago, source: Seeking Alpha

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...

Intellia Therapeutics, Inc.

2mon ago, source: CNN

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...

Pliant Therapeutics, Inc.

1mon ago, source: CNN

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a ...

Viking Therapeutics Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

PTC Therapeutics Inc (PTCT)

7mon ago, source: Investing

It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...